Physician profile
Steven Mark Skinner
NPI 1295727048
$358.41
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.26 · 2020: $128 · 2021: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $73.00 | 2019-2021 | |
| Pfizer INC. | $54.50 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $48.87 | 2020 | |
| Almirall LLC | $40.28 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.81 | 2021 | |
| Abbvie INC. | $27.15 | 2021 | |
| Dusa Pharmaceuticals, INC. | $24.00 | 2019 | |
| Genzyme Corporation | $21.41 | 2021 | |
| Biofrontera INC. | $17.03 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.